WallStSmart

InterCure Ltd. (INCR)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 7036% more annual revenue ($17.35B vs $243.12M). TEVA leads profitability with a 9.0% profit margin vs -13.2%. TEVA earns a higher WallStSmart Score of 66/100 (B-).

INCR

Hold

38

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.62

TEVA

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 7.0Value: 6.3Quality: 4.0
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INCR2 strengths · Avg: 9.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
23.9%8/10

Revenue surging 23.9% year-over-year

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.858/10

Growing faster than its price suggests

Areas to Watch

INCR4 concerns · Avg: 2.5/10
Market CapQuality
$55.23M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Return on EquityProfitability
-9.0%2/10

ROE of -9.0% — below average capital efficiency

EPS GrowthGrowth
-84.7%2/10

Earnings declined 84.7%

TEVA4 concerns · Avg: 3.0/10
P/E RatioValuation
25.8x4/10

Moderate valuation

Revenue GrowthGrowth
2.3%4/10

2.3% revenue growth

Free Cash FlowQuality
$-208.00M2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : INCR

The strongest argument for INCR centers on Price/Book, Revenue Growth. Revenue growth of 23.9% demonstrates continued momentum.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.

Bear Case : INCR

The primary concerns for INCR are Market Cap, Operating Margin, Return on Equity.

Bear Case : TEVA

The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Key Dynamics to Monitor

INCR profiles as a growth stock while TEVA is a value play — different risk/reward profiles.

TEVA carries more volatility with a beta of 0.85 — expect wider price swings.

INCR is growing revenue faster at 23.9% — sustainability is the question.

INCR generates stronger free cash flow (13M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (66/100 vs 38/100). Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InterCure Ltd.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Syneos Health, Inc., a contract research organization, provides various clinical development services for the medical device and biopharmaceutical industries in North America, Europe, the Middle East and Africa, Asia-Pacific, and Latin America. The company is headquartered in Raleigh, North Carolina.

Visit Website →

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?